A China Phase I, Open Label, Multi-Center, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs BGB 290 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Sponsors BeiGene
- 21 Dec 2016 According to a BeiGene Ltd. media release, Professor Binghe Xu from The Chinese Academy of Medical Sciences Cancer Hospital is the principal investigator of the study.
- 21 Dec 2016 According to a BeiGene Ltd. media release, the first patient has been dosed in this trial.
- 21 Dec 2016 According to a BeiGene Ltd. media release, status changed from planning to recruiting.